{"id":"kit","name":"KIT","symbol":"KIT","route":"/targets/kit/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6342","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000157404","uniprot":"https://www.uniprot.org/uniprotkb/P10721/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P10721","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1936","open-targets":"https://platform.opentargets.org/target/ENSG00000157404","civic":"https://civicdb.org/genes/3815/summary","oncokb":"https://www.oncokb.org/gene/KIT","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=KIT","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=KIT","depmap":"https://depmap.org/portal/gene/KIT?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000157404-KIT","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/3815","omim":"https://www.omim.org/entry/164920"}],"products":[{"id":"al2846","name":"AL2846","status":"phase-3","modality":"small molecule (structure undisclosed or not yet in PubChem)","route":"/drugs/al2846/"},{"id":"anlotinib","name":"Anlotinib","status":"approved","modality":"Small-molecule multi-kinase inhibitor (VEGFR, FGFR, PDGFR, KIT)","route":"/drugs/anlotinib/"},{"id":"avapritinib","name":"Avapritinib","status":"approved","modality":"Small-molecule kinase inhibitor (PDGFRA D842V / KIT)","route":"/drugs/avapritinib/"},{"id":"bezuclastinib","name":"Bezuclastinib","status":"phase-3","modality":"small molecule","route":"/drugs/bezuclastinib/"},{"id":"chiauranib","name":"Chiauranib","status":"phase-3","modality":"small molecule","route":"/drugs/chiauranib/"},{"id":"imatinib","name":"Imatinib","status":"approved","modality":"Small-molecule kinase inhibitor (BCR-ABL, KIT, PDGFRA)","route":"/drugs/imatinib/"},{"id":"lenvatinib","name":"Lenvatinib","status":"approved","modality":"Small-molecule multi-kinase inhibitor (VEGFR, FGFR, PDGFR, RET, KIT)","route":"/drugs/lenvatinib/"},{"id":"midostaurin","name":"Midostaurin","status":"approved","modality":"Small-molecule multikinase inhibitor (FLT3)","route":"/drugs/midostaurin/"},{"id":"nilotinib","name":"Nilotinib","status":"approved","modality":"Small-molecule BCR-ABL1 TKI (second generation)","route":"/drugs/nilotinib/"},{"id":"pazopanib","name":"Pazopanib","status":"approved","modality":"Small-molecule kinase inhibitor (VEGFR/PDGFR/KIT)","route":"/drugs/pazopanib/"},{"id":"pexidartinib","name":"Pexidartinib","status":"approved","modality":"Small-molecule CSF1R/KIT/FLT3 inhibitor","route":"/drugs/pexidartinib/"},{"id":"regorafenib","name":"Regorafenib","status":"approved","modality":"Small-molecule multi-kinase inhibitor","route":"/drugs/regorafenib/"},{"id":"ripretinib","name":"Ripretinib","status":"approved","modality":"Small-molecule kinase inhibitor (KIT/PDGFRA switch-control)","route":"/drugs/ripretinib/"},{"id":"sunitinib","name":"Sunitinib","status":"approved","modality":"Small-molecule multi-kinase inhibitor (VEGFR, PDGFR, KIT)","route":"/drugs/sunitinib/"}],"trials":[{"id":"nct04194775","name":"A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma","nct":"NCT04194775","phase":"3","status":"active"},{"id":"nct05456191","name":"A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)","nct":"NCT05456191","phase":"3","status":"active"},{"id":"emerald-3","name":"EMERALD-3","nct":"NCT05301842","phase":"3","status":"positive"},{"id":"nct04586231","name":"LITESPARK-011","nct":"NCT04586231","phase":"3","status":"positive"},{"id":"litespark-012","name":"LITESPARK-012","nct":"NCT04736706","phase":"3","status":"negative"},{"id":"nct04971226","name":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP","nct":"NCT04971226","phase":"3","status":"active"},{"id":"nct03829462","name":"Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients","nct":"NCT03829462","phase":"3","status":"active"},{"id":"nct03673501","name":"A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib","nct":"NCT03673501","phase":"3","status":"active"},{"id":"leap-012","name":"LEAP-012","nct":"NCT04246177","phase":"3","status":"mixed"},{"id":"phallcon","name":"PhALLCON","nct":"NCT03589326","phase":"3","status":"positive"},{"id":"nct04488822","name":"A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT","nct":"NCT04488822","phase":"3","status":"active"},{"id":"leap-002","name":"LEAP-002","nct":"NCT03713593","phase":"3","status":"negative"},{"id":"clear","name":"CLEAR (KEYNOTE-581)","nct":"NCT02811861","phase":"3","status":"positive"},{"id":"keynote-775","name":"KEYNOTE-775 / Study 309","nct":"NCT03517449","phase":"3","status":"positive"},{"id":"checkmate-9er","name":"CheckMate 9ER","nct":"NCT03141177","phase":"3","status":"positive"},{"id":"invictus","name":"INVICTUS","nct":"NCT03353753","phase":"3","status":"positive"},{"id":"nct03091192","name":"Savolitinib vs. Sunitinib in MET-driven PRCC.","nct":"NCT03091192","phase":"3","status":"active"},{"id":"voyager","name":"VOYAGER","nct":"NCT03465722","phase":"3","status":"negative"},{"id":"enliven","name":"ENLIVEN","nct":"NCT02371369","phase":"3","status":"positive"},{"id":"imblaze370","name":"IMblaze370","nct":"NCT02788279","phase":"3","status":"negative"},{"id":"keynote-426","name":"KEYNOTE-426","nct":"NCT02853331","phase":"3","status":"positive"},{"id":"nct03260894","name":"Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)","nct":"NCT03260894","phase":"3","status":"completed"},{"id":"tappas","name":"TAPPAS","nct":"NCT02979899","phase":"3","status":"negative"},{"id":"carmena","name":"CARMENA","nct":"NCT00930033","phase":"3","status":"positive"},{"id":"checkmate-214","name":"CheckMate 214","nct":"NCT02231749","phase":"3","status":"positive"},{"id":"reflect","name":"REFLECT","nct":"NCT01761266","phase":"3","status":"positive"},{"id":"ratify","name":"RATIFY (CALGB 10603)","nct":"NCT00651261","phase":"3","status":"positive"},{"id":"resorce","name":"RESORCE","nct":"NCT01774344","phase":"3","status":"positive"},{"id":"concur","name":"CONCUR","nct":"NCT01584830","phase":"3","status":"positive"},{"id":"correct","name":"CORRECT","nct":"NCT01103323","phase":"3","status":"positive"},{"id":"grid","name":"GRID","nct":"NCT01271712","phase":"3","status":"positive"},{"id":"ssgxviii","name":"SSGXVIII/AIO (adjuvant imatinib in GIST)","nct":"NCT00116935","phase":"3","status":"positive"},{"id":"dasision","name":"DASISION","nct":"NCT00481247","phase":"3","status":"positive"},{"id":"nct05208047","name":"(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors","nct":"NCT05208047","phase":"3","status":"recruiting"},{"id":"nct06469879","name":"A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients","nct":"NCT06469879","phase":"3","status":"planned"},{"id":"nct03459534","name":"A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs","nct":"NCT03459534","phase":"3","status":"recruiting"},{"id":"nct06048315","name":"A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs W","nct":"NCT06048315","phase":"3","status":"planned"},{"id":"nct07728955","name":"A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for","nct":"NCT07728955","phase":"3","status":"planned"},{"id":"nct07730489","name":"A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, F","nct":"NCT07730489","phase":"3","status":"planned"},{"id":"nct06371157","name":"A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepat","nct":"NCT06371157","phase":"3","status":"recruiting"},{"id":"nct06860971","name":"A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma","nct":"NCT06860971","phase":"3","status":"recruiting"},{"id":"nct04854668","name":"A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Can","nct":"NCT04854668","phase":"3","status":"active"},{"id":"nct03729245","name":"A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)","nct":"NCT03729245","phase":"3"},{"id":"nct05899049","name":"A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study","nct":"NCT05899049","phase":"3","status":"active"},{"id":"aldoxorubicin-phase-3-sts","name":"Aldoxorubicin versus investigator's choice in relapsed or refractory soft tissue sarcoma","nct":"NCT02049905","phase":"3","status":"negative"},{"id":"nct05862337","name":"Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.","nct":"NCT05862337","phase":"3","status":"recruiting"},{"id":"nct07443397","name":"Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.","nct":"NCT07443397","phase":"3","status":"recruiting"},{"id":"nct04921527","name":"Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer","nct":"NCT04921527","phase":"3","status":"recruiting"},{"id":"nct07405164","name":"Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)","nct":"NCT07405164","phase":"3","status":"recruiting"},{"id":"nct06199973","name":"Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, ","nct":"NCT06199973","phase":"3","status":"active"},{"id":"insight-gist","name":"INSIGHT","nct":"NCT05734105","phase":"3","status":"active"},{"id":"nct03784014","name":"Molecular Profiling of Advanced Soft-tissue Sarcomas","nct":"NCT03784014","phase":"3","status":"completed"},{"id":"nct03016819","name":"Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)","nct":"NCT03016819","phase":"3","status":"recruiting"},{"id":"nct03722420","name":"Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)","nct":"NCT03722420","phase":"3","status":"active"},{"id":"nct05794971","name":"Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases","nct":"NCT05794971","phase":"3","status":"recruiting"},{"id":"nct05043090","name":"Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC","nct":"NCT05043090","phase":"3","status":"active"},{"id":"nct05425940","name":"Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer","nct":"NCT05425940","phase":"3","status":"active"},{"id":"nct07134205","name":"The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer","nct":"NCT07134205","phase":"3","status":"planned"},{"id":"nct06441344","name":"Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell","nct":"NCT06441344","phase":"3","status":"planned"},{"id":"alter-0303","name":"ALTER 0303","nct":"NCT02388919","phase":"2/3","status":"positive"},{"id":"nct04322617","name":"Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer","nct":"NCT04322617","phase":"2/3","status":"recruiting"},{"id":"nct06662877","name":"Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment","nct":"NCT06662877","phase":"2/3","status":"planned"},{"id":"nct07636226","name":"QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer","nct":"NCT07636226","phase":"2/3","status":"planned"},{"id":"nct05462613","name":"Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer","nct":"NCT05462613","phase":"2/3","status":"recruiting"},{"id":"gbm-agile","name":"GBM AGILE","nct":"NCT03970447","phase":"platform","status":"recruiting"},{"id":"nci-match","name":"NCI-MATCH (EAY131)","nct":"NCT02465060","phase":"platform","status":"active"},{"id":"firstmappp","name":"FIRSTMAPPP","nct":"NCT01371201","phase":"2","status":"positive"},{"id":"papmet","name":"PAPMET (SWOG S1500)","nct":"NCT02761057","phase":"2","status":"positive"},{"id":"tapur","name":"TAPUR (Targeted Agent and Profiling Utilization Registry)","nct":"NCT02693535","phase":"2","status":"recruiting"},{"id":"regobone","name":"REGOBONE","nct":"NCT02389244","phase":"2","status":"positive"},{"id":"esphall","name":"EsPhALL (EsPhALL2004 and EsPhALL2010)","nct":"NCT00287105","phase":"2","status":"completed"},{"id":"nct06829355","name":"\"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer\"","nct":"NCT06829355","phase":"2","status":"recruiting"},{"id":"nct04996875","name":"(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis","nct":"NCT04996875","phase":"2","status":"recruiting"},{"id":"nct03731260","name":"(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo ","nct":"NCT03731260","phase":"2","status":"active"},{"id":"nct05186753","name":"(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis","nct":"NCT05186753","phase":"2","status":"active"},{"id":"nct06887218","name":"5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer","nct":"NCT06887218","phase":"2","status":"recruiting"},{"id":"nct05913089","name":"A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer","nct":"NCT05913089","phase":"2","status":"recruiting"},{"id":"nct03591510","name":"A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML","nct":"NCT03591510","phase":"2","status":"active"},{"id":"nct07562581","name":"A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC","nct":"NCT07562581","phase":"2","status":"recruiting"},{"id":"nct07679399","name":"A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.","nct":"NCT07679399","phase":"2","status":"recruiting"},{"id":"nct01503502","name":"A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia","nct":"NCT01503502","phase":"2"},{"id":"nct07815223","name":"A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC","nct":"NCT07815223","phase":"2","status":"recruiting"},{"id":"nct07099794","name":"A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen","nct":"NCT07099794","phase":"2","status":"planned"},{"id":"nct07538271","name":"A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer","nct":"NCT07538271","phase":"2","status":"planned"},{"id":"nct06962787","name":"A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer","nct":"NCT06962787","phase":"2","status":"recruiting"},{"id":"nct06246643","name":"A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies","nct":"NCT06246643","phase":"2","status":"active"},{"id":"nct07087158","name":"A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma","nct":"NCT07087158","phase":"2","status":"recruiting"},{"id":"nct07282262","name":"An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.","nct":"NCT07282262","phase":"2","status":"recruiting"},{"id":"nct02955940","name":"An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib","nct":"NCT02955940","phase":"2","status":"active"},{"id":"nct07398326","name":"Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer","nct":"NCT07398326","phase":"2","status":"recruiting"},{"id":"nct07635290","name":"Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer","nct":"NCT07635290","phase":"2","status":"active"},{"id":"nct04771520","name":"Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors","nct":"NCT04771520","phase":"2","status":"recruiting"},{"id":"nct06901622","name":"Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma","nct":"NCT06901622","phase":"2","status":"recruiting"},{"id":"nct06992336","name":"Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy","nct":"NCT06992336","phase":"2","status":"recruiting"},{"id":"nct06767813","name":"Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms","nct":"NCT06767813","phase":"2","status":"recruiting"},{"id":"nct07548177","name":"Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma","nct":"NCT07548177","phase":"2","status":"recruiting"},{"id":"nct07829874","name":"Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.","nct":"NCT07829874","phase":"2","status":"planned"},{"id":"nct05057052","name":"Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis","nct":"NCT05057052","phase":"2","status":"recruiting"},{"id":"nct07159217","name":"Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer","nct":"NCT07159217","phase":"2","status":"planned"},{"id":"nct07081633","name":"Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma","nct":"NCT07081633","phase":"2","status":"active"},{"id":"nct06949982","name":"Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Co","nct":"NCT06949982","phase":"2","status":"recruiting"},{"id":"nct06028633","name":"Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients","nct":"NCT06028633","phase":"2","status":"planned"},{"id":"nct06963060","name":"Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)","nct":"NCT06963060","phase":"2","status":"recruiting"},{"id":"nct06558773","name":"GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.","nct":"NCT06558773","phase":"2","status":"recruiting"},{"id":"nct06389500","name":"HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer","nct":"NCT06389500","phase":"2","status":"planned"},{"id":"nct06849492","name":"HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer","nct":"NCT06849492","phase":"2","status":"planned"},{"id":"nct07263360","name":"Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer","nct":"NCT07263360","phase":"2","status":"planned"},{"id":"nct05985109","name":"KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer","nct":"NCT05985109","phase":"2","status":"recruiting"},{"id":"nct07406633","name":"KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)","nct":"NCT07406633","phase":"2","status":"recruiting"},{"id":"nct05170438","name":"Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment","nct":"NCT05170438","phase":"2","status":"active"},{"id":"nct06919848","name":"Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)","nct":"NCT06919848","phase":"2","status":"planned"},{"id":"nct05903833","name":"Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surge","nct":"NCT05903833","phase":"2","status":"recruiting"},{"id":"nct04976634","name":"Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)","nct":"NCT04976634","phase":"2","status":"active"},{"id":"nct06230471","name":"Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer","nct":"NCT06230471","phase":"2","status":"recruiting"},{"id":"nct04846634","name":"Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (A","nct":"NCT04846634","phase":"2","status":"planned"},{"id":"nct06852287","name":"Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer","nct":"NCT06852287","phase":"2","status":"recruiting"},{"id":"nct07530445","name":"Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer","nct":"NCT07530445","phase":"2","status":"recruiting"},{"id":"nct07670273","name":"Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer","nct":"NCT07670273","phase":"2","status":"recruiting"},{"id":"nct07704177","name":"Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer","nct":"NCT07704177","phase":"2","status":"recruiting"},{"id":"nct07310173","name":"Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma","nct":"NCT07310173","phase":"2","status":"recruiting"},{"id":"nct06892925","name":"QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors","nct":"NCT06892925","phase":"2","status":"active"},{"id":"nct07110064","name":"QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer","nct":"NCT07110064","phase":"2","status":"recruiting"},{"id":"nct07601178","name":"QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride","nct":"NCT07601178","phase":"2","status":"recruiting"},{"id":"nct06911684","name":"Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.","nct":"NCT06911684","phase":"2","status":"recruiting"},{"id":"nct07071961","name":"Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Di","nct":"NCT07071961","phase":"2","status":"recruiting"},{"id":"nct05963490","name":"Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer","nct":"NCT05963490","phase":"2","status":"recruiting"},{"id":"nct06425133","name":"Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers","nct":"NCT06425133","phase":"2","status":"recruiting"},{"id":"nct07501169","name":"Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)","nct":"NCT07501169","phase":"2","status":"planned"},{"id":"nct07025174","name":"Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer","nct":"NCT07025174","phase":"2","status":"recruiting"},{"id":"nct07213570","name":"STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer","nct":"NCT07213570","phase":"2","status":"recruiting"},{"id":"nct05112991","name":"Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer","nct":"NCT05112991","phase":"2","status":"recruiting"},{"id":"nct05775159","name":"Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer","nct":"NCT05775159","phase":"2","status":"active"},{"id":"nct05822752","name":"Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Bu","nct":"NCT05822752","phase":"2","status":"active"},{"id":"nct04701476","name":"TATE and Pembrolizumab (MK3475) in mCRC and NSCLC","nct":"NCT04701476","phase":"2","status":"recruiting"},{"id":"nct04875585","name":"Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC","nct":"NCT04875585","phase":"2","status":"recruiting"},{"id":"nct07219459","name":"Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)","nct":"NCT07219459","phase":"2","status":"recruiting"},{"id":"nct06682780","name":"A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours","nct":"NCT06682780","phase":"1/2","status":"recruiting"},{"id":"nct07040228","name":"A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer","nct":"NCT07040228","phase":"1/2","status":"recruiting"},{"id":"nct07750041","name":"A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer","nct":"NCT07750041","phase":"1/2","status":"planned"},{"id":"nct07269158","name":"A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer","nct":"NCT07269158","phase":"1/2","status":"planned"},{"id":"nct04008797","name":"A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor","nct":"NCT04008797","phase":"1/2","status":"active"},{"id":"nct05957367","name":"A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies","nct":"NCT05957367","phase":"1/2","status":"recruiting"},{"id":"nct05319730","name":"A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)","nct":"NCT05319730","phase":"1/2","status":"recruiting"},{"id":"nct04300556","name":"A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types","nct":"NCT04300556","phase":"1/2","status":"recruiting"},{"id":"nct04977453","name":"GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors","nct":"NCT04977453","phase":"1/2","status":"recruiting"},{"id":"nct07636798","name":"Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer","nct":"NCT07636798","phase":"1/2","status":"recruiting"},{"id":"nct06761027","name":"mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer","nct":"NCT06761027","phase":"1/2","status":"recruiting"},{"id":"nct05024214","name":"Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors","nct":"NCT05024214","phase":"1/2","status":"recruiting"},{"id":"nct07139470","name":"Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer","nct":"NCT07139470","phase":"1/2","status":"planned"},{"id":"nct06047379","name":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","nct":"NCT06047379","phase":"1/2","status":"recruiting"},{"id":"nct04938817","name":"Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)","nct":"NCT04938817","phase":"1/2","status":"active"},{"id":"nct02861573","name":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","nct":"NCT02861573","phase":"1/2","status":"active"},{"id":"nct04626479","name":"Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)","nct":"NCT04626479","phase":"1/2","status":"active"},{"id":"nct04626518","name":"Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)","nct":"NCT04626518","phase":"1/2","status":"active"},{"id":"nct06140576","name":"The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breas","nct":"NCT06140576","phase":"1/2","status":"planned"},{"id":"nct04781192","name":"The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers","nct":"NCT04781192","phase":"1/2","status":"active"},{"id":"nct06456138","name":"Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC","nct":"NCT06456138","phase":"1/2","status":"planned"},{"id":"explorer","name":"EXPLORER","nct":"NCT02561988","phase":"1","status":"positive"},{"id":"navigator","name":"NAVIGATOR","nct":"NCT02508532","phase":"1","status":"positive"}],"pathways":["aml-signalling"],"companies":["bayer","blueprint-medicines","celldex","chipscreen","cogent-biosciences","daiichi-sankyo","deciphera","eisai","merck","natco","novartis","pfizer","sanofi","sino-biopharm"],"keyPapers":["paper-lemmon-schlessinger-rtk-signalling-cell-2010"],"hotspots":[{"label":"Exon 11 (W557_K558del, V559D, V560D, L576P)","position":557,"kind":"activating","frequency":"About two thirds of GIST","drugs":["imatinib","sunitinib","regorafenib","ripretinib"]},{"label":"Exon 9 (A502_Y503dup)","position":502,"kind":"activating","frequency":"About 10% of GIST","drugs":["imatinib","sunitinib","ripretinib"]},{"label":"V654A / T670I (exons 13 to 14)","position":654,"kind":"resistance","drugs":["sunitinib","ripretinib"]},{"label":"D816V / N822K / A829P (exons 17 to 18)","position":816,"kind":"resistance","drugs":["avapritinib","ripretinib","regorafenib"]}],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}